Incretin-Based Therapies for the Treatment of Binge Eating-A Systematic Review.

White RT, Henriquez P, Innocent B, Bullers K, Elmaoued A

Pharmacotherapy1 May 2026Cited by 2 (Europe PMC)

PMID41947645DOI10.1002/phar.70135PepBankPUB-41947645

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study16

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone16

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

01HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In people with diagnosed binge-eating disorder or binge-eating behaviors, incretin therapies including liraglutide were associated with improved Binge Eating Scale scores.
In plain wordsIn people with binge-eating disorder or binge-eating behaviors, incretin therapies were linked to improved Binge Eating Scale scores.
Peptide
Liraglutide
Outcome
DecreaseBinge Eating Scale scores
Study
n: not reported in source
Outcome group
Psychiatric symptoms · Mental health and mood
Source sentences
Summary
Despite heterogeneity in study design and outcome measures, consistent reductions in binge eating behaviors were observed, reflected by improvements in Binge Eating Scale scores, reductions in binge frequency, and remission rates.
4 context sentences(design, population, supporting numbers)
Summary · context
This systematic review was registered with PROSPERO (CRD42024615851) and conducted in accordance with PRISMA 2020 guidelines.
Summary · context
Comprehensive searches were performed across MEDLINE, Embase, PsycINFO, Scopus, and Cochrane CENTRAL from inception to December 2024.
Summary · context
Eligible studies included human trials evaluating GLP-1 RAs or dual GLP-1/GIP agonists in patients with diagnosed BED or binge eating behaviors.
Summary · context
Interventions studied included liraglutide, semaglutide, and dulaglutide, with sample sizes generally < 75 participants.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4194764501
02HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In people with diagnosed binge-eating disorder or binge-eating behaviors, incretin therapies including semaglutide were associated with improved Binge Eating Scale scores.
In plain wordsIn people with binge-eating disorder or binge-eating behaviors, incretin therapies were linked to improved Binge Eating Scale scores.
Peptide
Semaglutide
Outcome
DecreaseBinge Eating Scale scores
Study
n: not reported in source
Outcome group
Psychiatric symptoms · Mental health and mood
Source sentences
Summary
Despite heterogeneity in study design and outcome measures, consistent reductions in binge eating behaviors were observed, reflected by improvements in Binge Eating Scale scores, reductions in binge frequency, and remission rates.
4 context sentences(design, population, supporting numbers)
Summary · context
This systematic review was registered with PROSPERO (CRD42024615851) and conducted in accordance with PRISMA 2020 guidelines.
Summary · context
Comprehensive searches were performed across MEDLINE, Embase, PsycINFO, Scopus, and Cochrane CENTRAL from inception to December 2024.
Summary · context
Eligible studies included human trials evaluating GLP-1 RAs or dual GLP-1/GIP agonists in patients with diagnosed BED or binge eating behaviors.
Summary · context
Interventions studied included liraglutide, semaglutide, and dulaglutide, with sample sizes generally < 75 participants.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4194764502
03HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In people with diagnosed binge-eating disorder or binge-eating behaviors, GLP-1 receptor agonists including liraglutide were associated with significant body-weight reductions of -3 to -24 kg.
In plain wordsIn people with binge-eating disorder or binge eating behaviors, GLP-1 receptor agonists were linked to lower body weight.
Peptide
Liraglutide
Outcome
DecreaseBody weight
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Measurements
Body-weight reduction
−3 to −24 kg
reported range
Source sentences
Summary
GLP-1 RAs were also associated with significant reductions in body weight (-3 to -24 kg), BMI, and improvements in glycemic control among individuals with diabetes.
4 context sentences(design, population, supporting numbers)
Summary · context
This systematic review was registered with PROSPERO (CRD42024615851) and conducted in accordance with PRISMA 2020 guidelines.
Summary · context
Comprehensive searches were performed across MEDLINE, Embase, PsycINFO, Scopus, and Cochrane CENTRAL from inception to December 2024.
Summary · context
Eligible studies included human trials evaluating GLP-1 RAs or dual GLP-1/GIP agonists in patients with diagnosed BED or binge eating behaviors.
Summary · context
Interventions studied included liraglutide, semaglutide, and dulaglutide, with sample sizes generally < 75 participants.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4194764503
04HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In people with diagnosed binge-eating disorder or binge-eating behaviors, GLP-1 receptor agonists including semaglutide were associated with significant body-weight reductions of -3 to -24 kg.
In plain wordsIn people with binge-eating disorder or binge eating behaviors, GLP-1 receptor agonists were linked to lower body weight.
Peptide
Semaglutide
Outcome
DecreaseBody weight
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Measurements
Body-weight reduction
−3 to −24 kg
reported range
Source sentences
Summary
GLP-1 RAs were also associated with significant reductions in body weight (-3 to -24 kg), BMI, and improvements in glycemic control among individuals with diabetes.
4 context sentences(design, population, supporting numbers)
Summary · context
This systematic review was registered with PROSPERO (CRD42024615851) and conducted in accordance with PRISMA 2020 guidelines.
Summary · context
Comprehensive searches were performed across MEDLINE, Embase, PsycINFO, Scopus, and Cochrane CENTRAL from inception to December 2024.
Summary · context
Eligible studies included human trials evaluating GLP-1 RAs or dual GLP-1/GIP agonists in patients with diagnosed BED or binge eating behaviors.
Summary · context
Interventions studied included liraglutide, semaglutide, and dulaglutide, with sample sizes generally < 75 participants.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4194764504
05HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In people with diabetes and binge-eating disorder or behaviors, pooled GLP-1 receptor agonists including liraglutide were associated with improved glycemic control.
In plain wordsIn people with diabetes and binge-eating disorder or behaviors, pooled GLP-1 therapies were linked to improved glycemic control.
Peptide
Liraglutide
Outcome
Direction not reportedGlycemic control
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
GLP-1 RAs were also associated with significant reductions in body weight (-3 to -24 kg), BMI, and improvements in glycemic control among individuals with diabetes.
4 context sentences(design, population, supporting numbers)
Summary · context
This systematic review was registered with PROSPERO (CRD42024615851) and conducted in accordance with PRISMA 2020 guidelines.
Summary · context
Comprehensive searches were performed across MEDLINE, Embase, PsycINFO, Scopus, and Cochrane CENTRAL from inception to December 2024.
Summary · context
Eligible studies included human trials evaluating GLP-1 RAs or dual GLP-1/GIP agonists in patients with diagnosed BED or binge eating behaviors.
Summary · context
Interventions studied included liraglutide, semaglutide, and dulaglutide, with sample sizes generally < 75 participants.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4194764505
06HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In people with diabetes and binge-eating disorder or behaviors, pooled GLP-1 receptor agonists including semaglutide were associated with improved glycemic control.
In plain wordsIn people with diabetes and binge-eating disorder or behaviors, pooled GLP-1 therapies were linked to improved glycemic control.
Peptide
Semaglutide
Outcome
Direction not reportedGlycemic control
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
GLP-1 RAs were also associated with significant reductions in body weight (-3 to -24 kg), BMI, and improvements in glycemic control among individuals with diabetes.
4 context sentences(design, population, supporting numbers)
Summary · context
This systematic review was registered with PROSPERO (CRD42024615851) and conducted in accordance with PRISMA 2020 guidelines.
Summary · context
Comprehensive searches were performed across MEDLINE, Embase, PsycINFO, Scopus, and Cochrane CENTRAL from inception to December 2024.
Summary · context
Eligible studies included human trials evaluating GLP-1 RAs or dual GLP-1/GIP agonists in patients with diagnosed BED or binge eating behaviors.
Summary · context
Interventions studied included liraglutide, semaglutide, and dulaglutide, with sample sizes generally < 75 participants.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4194764506
07HumanNot a test of Liraglutide aloneSystematic reviewSafety outcome
In people with binge-eating disorder or behaviors, primarily gastrointestinal adverse effects were reported for pooled incretin therapies including liraglutide.
In plain wordsIn people with binge-eating disorder or binge eating behaviors, incretin therapies had primarily gastrointestinal adverse effects.
Peptide
Liraglutide
Outcome
Not applicableGastrointestinal adverse effects
Study
n: not reported in source
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Source sentences
Summary
Adverse effects were primarily gastrointestinal, with no new psychiatric safety concerns identified.
4 context sentences(design, population, supporting numbers)
Summary · context
This systematic review was registered with PROSPERO (CRD42024615851) and conducted in accordance with PRISMA 2020 guidelines.
Summary · context
Comprehensive searches were performed across MEDLINE, Embase, PsycINFO, Scopus, and Cochrane CENTRAL from inception to December 2024.
Summary · context
Eligible studies included human trials evaluating GLP-1 RAs or dual GLP-1/GIP agonists in patients with diagnosed BED or binge eating behaviors.
Summary · context
Interventions studied included liraglutide, semaglutide, and dulaglutide, with sample sizes generally < 75 participants.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4194764507
08HumanNot a test of Semaglutide aloneSystematic reviewSafety outcome
In people with binge-eating disorder or behaviors, primarily gastrointestinal adverse effects were reported for pooled incretin therapies including semaglutide.
In plain wordsIn people with binge-eating disorder or binge eating behaviors, incretin therapies had primarily gastrointestinal adverse effects.
Peptide
Semaglutide
Outcome
Not applicableGastrointestinal adverse effects
Study
n: not reported in source
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Source sentences
Summary
Adverse effects were primarily gastrointestinal, with no new psychiatric safety concerns identified.
4 context sentences(design, population, supporting numbers)
Summary · context
This systematic review was registered with PROSPERO (CRD42024615851) and conducted in accordance with PRISMA 2020 guidelines.
Summary · context
Comprehensive searches were performed across MEDLINE, Embase, PsycINFO, Scopus, and Cochrane CENTRAL from inception to December 2024.
Summary · context
Eligible studies included human trials evaluating GLP-1 RAs or dual GLP-1/GIP agonists in patients with diagnosed BED or binge eating behaviors.
Summary · context
Interventions studied included liraglutide, semaglutide, and dulaglutide, with sample sizes generally < 75 participants.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4194764508
09HumanNot a test of Liraglutide aloneSystematic reviewSafety outcome
In people with binge-eating disorder or behaviors, no new psychiatric safety concerns were identified for pooled incretin therapies including liraglutide.
In plain wordsIn people with binge-eating disorder or binge eating behaviors, no new psychiatric safety concerns were identified for incretin therapies.
Peptide
Liraglutide
Outcome
Not applicablePsychiatric safety concerns
Study
n: not reported in source
Outcome group
Adverse events · Mental health and mood
Source sentences
Summary
Adverse effects were primarily gastrointestinal, with no new psychiatric safety concerns identified.
4 context sentences(design, population, supporting numbers)
Summary · context
This systematic review was registered with PROSPERO (CRD42024615851) and conducted in accordance with PRISMA 2020 guidelines.
Summary · context
Comprehensive searches were performed across MEDLINE, Embase, PsycINFO, Scopus, and Cochrane CENTRAL from inception to December 2024.
Summary · context
Eligible studies included human trials evaluating GLP-1 RAs or dual GLP-1/GIP agonists in patients with diagnosed BED or binge eating behaviors.
Summary · context
Interventions studied included liraglutide, semaglutide, and dulaglutide, with sample sizes generally < 75 participants.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4194764509
10HumanNot a test of Semaglutide aloneSystematic reviewSafety outcome
In people with binge-eating disorder or behaviors, no new psychiatric safety concerns were identified for pooled incretin therapies including semaglutide.
In plain wordsIn people with binge-eating disorder or binge eating behaviors, no new psychiatric safety concerns were identified for incretin therapies.
Peptide
Semaglutide
Outcome
Not applicablePsychiatric safety concerns
Study
n: not reported in source
Outcome group
Adverse events · Mental health and mood
Source sentences
Summary
Adverse effects were primarily gastrointestinal, with no new psychiatric safety concerns identified.
4 context sentences(design, population, supporting numbers)
Summary · context
This systematic review was registered with PROSPERO (CRD42024615851) and conducted in accordance with PRISMA 2020 guidelines.
Summary · context
Comprehensive searches were performed across MEDLINE, Embase, PsycINFO, Scopus, and Cochrane CENTRAL from inception to December 2024.
Summary · context
Eligible studies included human trials evaluating GLP-1 RAs or dual GLP-1/GIP agonists in patients with diagnosed BED or binge eating behaviors.
Summary · context
Interventions studied included liraglutide, semaglutide, and dulaglutide, with sample sizes generally < 75 participants.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4194764510
11HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In people with diagnosed binge-eating disorder or binge-eating behaviors, incretin therapies including liraglutide were associated with reduced binge frequency.
In plain wordsIn people with binge-eating disorder or binge eating behaviors, incretin therapies were linked to reduced binge frequency.
Peptide
Liraglutide
Outcome
DecreaseBinge frequency
Study
n: not reported in source
Outcome group
Psychiatric symptoms · Mental health and mood
Source sentences
Summary
Despite heterogeneity in study design and outcome measures, consistent reductions in binge eating behaviors were observed, reflected by improvements in Binge Eating Scale scores, reductions in binge frequency, and remission rates.
4 context sentences(design, population, supporting numbers)
Summary · context
This systematic review was registered with PROSPERO (CRD42024615851) and conducted in accordance with PRISMA 2020 guidelines.
Summary · context
Comprehensive searches were performed across MEDLINE, Embase, PsycINFO, Scopus, and Cochrane CENTRAL from inception to December 2024.
Summary · context
Eligible studies included human trials evaluating GLP-1 RAs or dual GLP-1/GIP agonists in patients with diagnosed BED or binge eating behaviors.
Summary · context
Interventions studied included liraglutide, semaglutide, and dulaglutide, with sample sizes generally < 75 participants.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4194764511
12HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In people with diagnosed binge-eating disorder or binge-eating behaviors, incretin therapies including semaglutide were associated with reduced binge frequency.
In plain wordsIn people with binge-eating disorder or binge eating behaviors, incretin therapies were linked to reduced binge frequency.
Peptide
Semaglutide
Outcome
DecreaseBinge frequency
Study
n: not reported in source
Outcome group
Psychiatric symptoms · Mental health and mood
Source sentences
Summary
Despite heterogeneity in study design and outcome measures, consistent reductions in binge eating behaviors were observed, reflected by improvements in Binge Eating Scale scores, reductions in binge frequency, and remission rates.
4 context sentences(design, population, supporting numbers)
Summary · context
This systematic review was registered with PROSPERO (CRD42024615851) and conducted in accordance with PRISMA 2020 guidelines.
Summary · context
Comprehensive searches were performed across MEDLINE, Embase, PsycINFO, Scopus, and Cochrane CENTRAL from inception to December 2024.
Summary · context
Eligible studies included human trials evaluating GLP-1 RAs or dual GLP-1/GIP agonists in patients with diagnosed BED or binge eating behaviors.
Summary · context
Interventions studied included liraglutide, semaglutide, and dulaglutide, with sample sizes generally < 75 participants.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4194764512
13HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In people with diagnosed binge-eating disorder or binge-eating behaviors, GLP-1 receptor agonists including liraglutide were associated with reduced body mass index.
In plain wordsIn people with binge-eating disorder or binge eating behaviors, GLP-1 receptor agonists were linked to lower BMI.
Peptide
Liraglutide
Outcome
DecreaseBody mass index
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
GLP-1 RAs were also associated with significant reductions in body weight (-3 to -24 kg), BMI, and improvements in glycemic control among individuals with diabetes.
4 context sentences(design, population, supporting numbers)
Summary · context
This systematic review was registered with PROSPERO (CRD42024615851) and conducted in accordance with PRISMA 2020 guidelines.
Summary · context
Comprehensive searches were performed across MEDLINE, Embase, PsycINFO, Scopus, and Cochrane CENTRAL from inception to December 2024.
Summary · context
Eligible studies included human trials evaluating GLP-1 RAs or dual GLP-1/GIP agonists in patients with diagnosed BED or binge eating behaviors.
Summary · context
Interventions studied included liraglutide, semaglutide, and dulaglutide, with sample sizes generally < 75 participants.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4194764513
14HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In people with diagnosed binge-eating disorder or binge-eating behaviors, GLP-1 receptor agonists including semaglutide were associated with reduced body mass index.
In plain wordsIn people with binge-eating disorder or binge eating behaviors, GLP-1 receptor agonists were linked to lower BMI.
Peptide
Semaglutide
Outcome
DecreaseBody mass index
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Source sentences
Summary
GLP-1 RAs were also associated with significant reductions in body weight (-3 to -24 kg), BMI, and improvements in glycemic control among individuals with diabetes.
4 context sentences(design, population, supporting numbers)
Summary · context
This systematic review was registered with PROSPERO (CRD42024615851) and conducted in accordance with PRISMA 2020 guidelines.
Summary · context
Comprehensive searches were performed across MEDLINE, Embase, PsycINFO, Scopus, and Cochrane CENTRAL from inception to December 2024.
Summary · context
Eligible studies included human trials evaluating GLP-1 RAs or dual GLP-1/GIP agonists in patients with diagnosed BED or binge eating behaviors.
Summary · context
Interventions studied included liraglutide, semaglutide, and dulaglutide, with sample sizes generally < 75 participants.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4194764514
15HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In people with diagnosed binge-eating disorder or binge-eating behaviors, the systematic review reported remission rates for incretin therapies including liraglutide.
In plain wordsIn people with binge-eating disorder or binge eating behaviors, the review reported remission rates for incretin therapies.
Peptide
Liraglutide
Outcome
Not applicableRemission rates
Study
n: not reported in source
Outcome group
Psychiatric symptoms · Mental health and mood
Source sentences
Summary
Despite heterogeneity in study design and outcome measures, consistent reductions in binge eating behaviors were observed, reflected by improvements in Binge Eating Scale scores, reductions in binge frequency, and remission rates.
4 context sentences(design, population, supporting numbers)
Summary · context
This systematic review was registered with PROSPERO (CRD42024615851) and conducted in accordance with PRISMA 2020 guidelines.
Summary · context
Comprehensive searches were performed across MEDLINE, Embase, PsycINFO, Scopus, and Cochrane CENTRAL from inception to December 2024.
Summary · context
Eligible studies included human trials evaluating GLP-1 RAs or dual GLP-1/GIP agonists in patients with diagnosed BED or binge eating behaviors.
Summary · context
Interventions studied included liraglutide, semaglutide, and dulaglutide, with sample sizes generally < 75 participants.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4194764515
16HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome
In people with diagnosed binge-eating disorder or binge-eating behaviors, the systematic review reported remission rates for incretin therapies including semaglutide.
In plain wordsIn people with binge-eating disorder or binge eating behaviors, the review reported remission rates for incretin therapies.
Peptide
Semaglutide
Outcome
Not applicableRemission rates
Study
n: not reported in source
Outcome group
Psychiatric symptoms · Mental health and mood
Source sentences
Summary
Despite heterogeneity in study design and outcome measures, consistent reductions in binge eating behaviors were observed, reflected by improvements in Binge Eating Scale scores, reductions in binge frequency, and remission rates.
4 context sentences(design, population, supporting numbers)
Summary · context
This systematic review was registered with PROSPERO (CRD42024615851) and conducted in accordance with PRISMA 2020 guidelines.
Summary · context
Comprehensive searches were performed across MEDLINE, Embase, PsycINFO, Scopus, and Cochrane CENTRAL from inception to December 2024.
Summary · context
Eligible studies included human trials evaluating GLP-1 RAs or dual GLP-1/GIP agonists in patients with diagnosed BED or binge eating behaviors.
Summary · context
Interventions studied included liraglutide, semaglutide, and dulaglutide, with sample sizes generally < 75 participants.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4194764516

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 2
9 Oct 2026, 03:06 UTC
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Incretin-Based Therapies for the Treatment of Binge Eating-A Systematic Review.

Summary

Results from this study16

Studies that did not test the peptide alone16

Version history

Subjects

Publication types

MeSH terms

Keywords